From patent to brand: the Aspirin case as a lesson in industrial property strategy

In the world of innovation, the protection of intangible assets often determines the difference between fleeting success and sustained leadership over time. The Aspirin case is a paradigmatic example: a chemical product developed at the end of the 19th century that, thanks to the strategic management of industrial property, became one of the most widely recognised medicines in the world.

What makes this story particularly interesting is not the chemistry of acetylsalicylic acid, nor even its therapeutic effects, but rather the way in which different intellectual property instruments—patents, trademarks and differentiation strategies—were used to maintain the product’s relevance beyond the expiration of its initial protection. Analysing this case allows us to extract lessons that remain applicable today in sectors as diverse as pharmaceuticals, digital technology or the automotive industry.

The patent as a starting point

When Bayer patented acetylsalicylic acid in 1899 in key markets such as the United States and the United Kingdom, it secured a period of exclusivity that limited competitors’ entry and allowed the recovery of investment in research and development. The patent functioned as it typically does in any sector: by granting a temporary monopoly that protects innovation.

However, the very nature of the patent system implies that exclusivity is limited in time and territorial in scope. The Aspirin case clearly illustrates the vulnerability of relying solely on a patent: protection was valid in certain countries but not in others, and it had a fixed expiration date. The strategic question was inevitable: what would happen to the business once that protection expired?

The trademark as a lasting asset

The answer came through branding. From the outset, Bayer focused on giving the product a distinctive name—Aspirin—and linking it to a strong corporate visual identity. This branding effort materialised in concrete elements: easily recognisable packaging, consumer-focused advertising and even the logo printed on the tablets themselves.

As a result, even after the patent expired, the public continued to associate the product with a specific origin. The registered trademark allowed commercial exclusivity to be extended into a space where competitors could only offer “generic acetylsalicylic acid”, while consumers continued to associate the word “Aspirin” with a standard of quality.

The transition from patent to trademark highlights the importance of designing an IP strategy that does not depend on a single legal instrument, but instead combines different layers of protection.

A combined IP strategy

Beyond the trademark, Bayer continued to develop new formulations and applications of acetylsalicylic acid, enabling it to register secondary patents.

For example, the effectiveness of aspirin in preventing heart attacks and strokes was discovered long after the original patent had expired. This ongoing innovation allowed Bayer to apply for new patents and maintain a competitive advantage.

This practice, known in the pharmaceutical industry as “evergreening”, does not always guarantee the same level of exclusivity as the original patent, but it does help maintain a degree of technological and market control.

The key lay in structuring a mixed industrial property portfolio:

• Initial patent as a barrier to entry.
• Registered trademark to ensure long-term recognition.
• Additional patents and improvements that partially extended exclusivity.
• Differentiated quality, reinforcing product perception in a growing generic market.

This approach anticipates what we now call “integrated IP strategies”: rather than relying on a single right, available tools are used in a complementary way to protect both technical innovation and market reputation.

The importance of marketing in the Aspirin case

Bayer did not limit itself to marketing an active ingredient, but deliberately worked to associate Aspirin with a reliable, consistent and safe product, even in a context where chemical equivalents already existed.

At the beginning of the 20th century, when the pharmaceutical market was marked by the circulation of medicines with dubious or outright adulterated formulations, the company’s strategy emphasised purity and pharmaceutical quality, clearly differentiating the product from copies and counterfeits. This differentiation was reinforced by a high degree of standardisation, both in the use of the name and logo and in packaging design, conveying the idea of a homogeneous, controlled product clearly identifiable by its corporate origin.

At the same time, communication efforts aimed at doctors and patients helped consolidate Aspirin not only as an effective medicine, but as a safe and trustworthy option. As a result, even after the patent expired, the strength of the distinctive sign allowed Bayer to maintain a differentiated market position and sell Aspirin at a higher price than generic acetylsalicylic acid, supported by the association between the name and a standard of quality.

External factors: IP and geopolitics

The Aspirin case also illustrates how industrial property does not develop in a vacuum, but within an international context subject to political change. After the First World War, Bayer lost trademark rights in several countries as a result of political decisions that redistributed the assets of German companies.

This episode serves as a reminder that the management of intangible assets must take into account external factors such as international treaties, trade tensions or armed conflicts. Today, clear parallels can be seen in debates on technology transfer, export restrictions or limitations on software protection in different territories. The lesson is clear: IP has a legal dimension, but also a geopolitical one that should not be underestimated.

Brand extension and diversification

The prestige of the Aspirin brand was not limited to a single product. Once consolidated, it served as an umbrella for other launches, allowing the company to leverage the recognition already acquired. This practice of brand extension is now common across many sectors: a strong brand becomes an asset that transcends the original product.

The case demonstrates that IP does not only protect what already exists, but can also serve as the foundation for future growth. A well-known brand acts as a platform for diversification and facilitates entry into new segments.

Lessons for today

More than a century later, the Aspirin example continues to offer valuable lessons for any organisation managing innovation and industrial property:

• Do not rely solely on patents. Technical exclusivity is valuable but finite; it must be complemented by other forms of protection.
• Invest in branding from the outset. Building identity while technical protection is in force ensures continuity once it expires.
• Design a mixed portfolio. Patents, trademarks, designs and trade secrets work best when managed together.
• Anticipate international scenarios. Territorial protection requires a global vision and preparation for regulatory or political change.
• Focus on quality as a differentiator. IP protects, but market trust consolidates long-term positioning.

Parallels with current sectors

The Aspirin model is replicated across different industries.

Apple, for example, combines patents and industrial designs with an extremely powerful brand that ensures loyalty beyond technical specifications. Tesla, on the other hand, has chosen to open part of its patent portfolio, relying instead on brand strength and its technological ecosystem to maintain leadership.

Post-it Notes (3M) emerged from a “failure” in the search for a strong adhesive. Initial patents provided exclusivity, but it was the trademark and distinctive design that transformed the product into an office icon, eventually becoming synonymous with sticky notes.

Lycra (DuPont), patented in 1962, became a registered trademark that survived long beyond technical protection. Even today, Lycra remains associated with quality in high-performance garments, despite the proliferation of generic alternatives.

In all these cases, the conclusion is similar: IP must be conceived as an integral strategy. An isolated patent may offer a temporary advantage, but only an approach combining different intangible assets guarantees long-term sustainability.

The omeprazole case: innovation without a brand legacy

Omeprazole, launched by AstraZeneca in the late 1980s under the brand Losec/Prilosec, revolutionised the treatment of acid reflux and peptic ulcers. Its patent protected it for over a decade and generated billions in revenue. However, once the patent expired, the brand did not survive in the collective imagination: the product quickly became identified by its generic name.

Unlike aspirin, which Bayer turned into a lasting brand asset even beyond patent protection, AstraZeneca failed to ensure that the brand endured once the patent expired (2001 in the US, earlier in other markets). The word that remained in the minds of doctors and patients was “omeprazole”. Today, although omeprazole remains one of the most prescribed and consumed medicines worldwide, the brand value built during the exclusivity period has largely disappeared.

This contrast illustrates a key point: a patent may guarantee temporary profitability, but only a comprehensive IP strategy—where the brand is reinforced as an intangible asset—ensures a lasting legacy.

The history of Aspirin is not merely that of a successful medicine, but a case study in industrial property management. Its current relevance lies in demonstrating that innovation does not end with product development, but continues in how it is protected, communicated and adapted over time.

For today’s companies, the message is clear:

IP should not be regarded as a legal formality, but as a strategic component of the business.

A patent may expire by its legal nature; a well-managed brand, by contrast, can accompany innovation for generations, provided it is built on a solid, technically sound and legally protected foundation.

Designing an effective industrial property strategy goes far beyond registering a patent or trademark. At H&A, we help you build an IP portfolio aligned with your business objectives, combining legal protection, strategic vision and long-term projection.

This analysis, prepared by Cristina Sendín, has been reported on by specialized media outlets such as Law & Trends.